




Final Results Year ended 31 March 2016



Disclaimer

The information in this document and the related presentation do not constitute or form any part of, and should not be construed as, an offer or invitation to sell, or issue, or any solicitation of any offer to purchase, subscribe for or otherwise acquire any share or other securities in Omega Diagnostics Group PLC ("Omega") in any jurisdiction, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this document and the presentation or their completeness. No representation or warranty, expressed or implied, is given on behalf of Omega or any of its respective directors, employees, agents or advisers as to the accuracy, completeness or fairness of the information or opinions contained herein or made in the presentation and, save in the case of fraud, no responsibility or liability is accepted (and all such liability is hereby excluded) for any such information or opinions.

Readers of this document and recipients of the presentation are reminded that any decision to acquire shares in Omega should be made only on the basis of information contained in the final admission document to be issued by Omega which may be different from the information contained in this document. The information in this document may not be reproduced or further distributed to any other person or published, in whole or in part, for any purpose. Neither this document (or any copy of it) nor the information in the presentation may be sent or taken into the United States, Canada, Australia or Japan, nor may it be distributed to any US person (within the meaning of regulation S under the US Securities Act of 1933, as amended).

Furthermore, this document and presentation are strictly only for persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (SI 2001/1335), as amended, (the "FPO") or persons falling within paragraph 49 of the FPO (high net worth companies, unincorporated associations etc.) or to persons to whom it may otherwise be lawful for these materials to be communicated ("Permitted Recipients"). Any persons who are not Permitted Recipients should not stay for the remainder of this presentation and, in any event, must not act or rely upon the information contained in this presentation and document. By staying for the remainder of this presentation and/or receiving this document, each participant is deemed to confirm that they are a Permitted Recipient.

Omega Presentation Team

- “ Andrew Shepherd – Chief Executive
- “ Colin King – Chief Operating Officer
- “ Kieron Harbinson – Chief Financial Officer
- “ Jag Grewal – Sales & Marketing Director


Introduction

- “ Financials
- “ Core business update
- “ Allergy update
- “ Visitect® CD4 update
- “ Pune update/Global Health
- “ Accelerated Growth Plans
- “ Summary


Financial KPIs

Year ending 31 March 2016


Sales (£m)
£12.7m ▲ 5%




Gross profit (%)
63.8% ▲ 40 bps



Adjusted PBT (£m)
£1.4m ▼ 2%



Adjusted EPS
1.2p ▼ 8%




Adjusted PBT stated before acquisition costs, share-based payments, IFRS-related discount unwinds and amortisation of intangible assets

Capitalised development – IAS38

Year ending 31 March 2016

Allersys® expenditure

Cumulative spend to date of £4.1m




£1,025k

▲ 5%

Visitect® CD4 expenditure

Cumulative spend to date of £1.6m



£487k

▲ 1%



Omega
DIAGNOSTICS
GROUP PLC

Group cash flow

Year ending 31 March 2016

	2016	2015
EBITDA	£1.3m	£1.4m
Working capital/other movements	£0.2m	(£0.3m)
Investing activity	(£2.0m)	(£2.0m)
Financing	(£0.2m)	(£0.2m)
Decrease in cash	(£0.7m)	(£1.1m)
Opening cash	£2.0m	£3.1m
Closing cash	£1.3m	£2.0m

Core Business

Allergy and Autoimmune

Main products:

- Allergozyme
- Allergodip
- Genesis Elisa

£3.2m (↓13%)

Food Intolerance

Main products:

- Genarrayt[®]/Foodprint[®] Microarray
- Food Detective[®]
- CNS laboratory service

£7.0m (19%)

Infectious Diseases

Main products:

- Immutrep Syphilis
- Micropath Bacterial tests
- Dengue Elisa

£2.5m (↓ 1%)


Flagship Product Sales

Year ending 31 March 2016

Genarrayt[®] Reagent Sales

Top five markets = 70% of sales


18 systems placed taking the total number of installations to 168



Food Detective[®] Sales

Top five markets = 62% of sales


Strong growth in Europe, Latin America and China



Core Business – Regional Highlights



Infectious disease performed well, particularly in Nigeria and Bangladesh offset by economic issues in Brazil
Food Intolerance continues to grow existing 'mature' EU markets as well as North America, China, Latin America and Middle East.



Continuing slow decline in domestic business.
Low rates of reimbursement making testing unattractive in smaller doctor practices.
Plan to reverse fortunes with Allergodip® / Allergodip® App for export markets.



Continued growth across all segments.
Increased focus on Food Intolerance products.
Growth in allergy with Allergodip® product line.
Investment in business development.

Allergy Segment



Core laboratory segment

- Automation
- Developed world markets
- Allersys® strategy



Mid market ELISA

- Semi-automated
- Declining market
- Holding strategy



Small lab / doctors office

- Manual
- Screening/panel tests
- Emerging markets
- Allergodip® / OmegApp strategy

Allersys®



41 allergens
optimised.



Beta sites



CE Mark



120+
allergens

Commercial Roadmap with IDS / mutual partners


VISITECT® CD4 Development Update

- “ Significant progress in addressing the ambient temperature effect
- “ We have developed a design that, if proven, would not require an external sample treatment method
- “ The new design has given encouraging results during internal testing indicating that there is no significant difference in test result between 20-35°C
- “ We are now gathering data from testing of patient samples at a large HIV testing laboratory
- “ We remain confident about the commercialisation of the test

Significant demand

Well documented and reinforced at the recent Diagnostic Manufacturers Meeting hosted by WHO & UNAIDS in Geneva (March 2016)


CD4 testing volumes are expected to remain roughly flat as countries increase patient initiation targets and scale up viral load monitoring



Note: Forecast based on scale-up in 21 high-ART patient burden countries and estimates for remaining low and middle-income countries. Need is estimated using projected ART patient numbers and testing guidelines, which incorporate implementation of test and treat in select countries.

18

Competitor Landscape



Rapid Test Manufacturing – Pune, India



- “ Opening ceremony Oct 2015
- “ Early performance data for malaria RDTs promising
- “ Manufacturing capacity for menu extension in Global Health:
 - “ Syphilis
 - “ Dengue
 - “ Chikungunya
 - “ Brucella
 - “ Leptospira
 - “ *S. typhi*



Growth opportunities

Leveraging
core business

Aligned
employees
committed to
continuous
improvement

Efficient,
effective &
compliant
processes

Framework
where ALL
employees
can contribute

Maintaining
customers at
the heart of
our
organisation

Accelerated
Growth

One
Company

Execute &
Deliver

Employees

Customer
Focus

Strategic Goals

Growth opportunities – Low Risk Development



Food Intolerance / Sensitivity

- Product improvements – Software & Automation
- Panel Extension – Regional Variants



Allergy


- Allersys® – Product expansion 40 to 120
- Allergodip® & App – Quantifying dipstick
- Panel Extension – Regional Variants



Global Health

- Pune Facility – Malaria, Dengue, Syphilis

Growth opportunities – Market Driven



Food Intolerance / Sensitivity

- CNS Market Expansion (USA) – Clinical Labs
- China via mid tier lab segment and consumer POC testing
- Grow existing markets



Allergy

- Mid Tier Lab segment via Allersys®
- Emerging markets via Allergodip® & App



Global Health


- NGO Network
- Leverage existing distributor base in resource poor countries

Summary

- “ Core business continues to perform well with significant growth opportunities in Food Intolerance
- “ 41 Allergen launch panel ready for commercialisation
- “ Visitect® CD4 . significant progress and remain confident of commercialisation of the test
- “ First product entering validation phase in our Pune manufacturing site
- “ A three year plan to maximise growth built on core business

APPENDICES

A Brief History



Omega Senior Management Team

